Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

18.99 +0.06 (+0.32%)
Streaming Delayed Price Updated: 10:25 AM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,081
Open 18.77
Bid (Size) 18.99 (5)
Ask (Size) 19.10 (3)
Prev. Close 18.93
Today's Range 18.51 - 19.41
52wk Range 8.795 - 34.12
Shares Outstanding 29,159,638
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Goldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To Know
 
Via Benzinga
Where BioXcel Therapeutics Stands With Analysts
 
Via Benzinga

Performance

YTD
-11.51%
-11.51%
1 Month
-18.04%
-18.04%
3 Month
-36.99%
-36.99%
6 Month
+1.39%
+1.39%
1 Year
+75.83%
+75.83%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Shares of BioXcel Therapeutics Are Dropping Thursday
Via The Motley Fool
BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
Via Benzinga
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
Via Investor's Business Daily
Looking Into BioXcel Therapeutics's Return On Capital Employed
Via Benzinga
BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment
Via Benzinga
Why These 3 Nasdaq Stocks Were Glowing Green This Week
Via The Motley Fool
The Latest Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Why BioXcel Therapeutics Stock Marched Higher Today
Via The Motley Fool
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
6 Analysts Have This to Say About BioXcel Therapeutics
Via Benzinga
Earnings Preview: BioXcel Therapeutics
Via Benzinga
Expert Ratings for BioXcel Therapeutics
Via Benzinga
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
Via Benzinga
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
Via Investor's Business Daily
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
Via Benzinga
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
Via Benzinga
ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google)
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.